Schrödinger provides advanced molecular simulations and enterprise software solutions and services to accelerate drug discovery.
As part of the strategic collaboration with Takeda, Schrödinger will lead the multi-year discovery effort for which it will be responsible for costs.
Takeda will provide structural biology support and has the option to exclusively license programs from Schrödinger later in discovery, including pre-clinical, clinical, and commercial milestones of up to $170m per program in addition to royalties on future sales. Other financial details were not disclosed.
According to Takeda, the collaboration combines Schrödinger’s in silico platform-driven drug discovery capabilities with Takeda’s therapeutic area knowledge and structural biology experience.
The deal follows a five-year early drug discovery collaboration signed with Sanofi in April 2015. The computational drug designer is providing target analysis and validation to lead identification and optimization for as many as ten drug discovery projects.